Pharmacist Lama Al.HomoudDirector of Clinical Pharmacy Directorate / MOH

MeTA Committee 1: Encouraging best practice & Improve Rational Use of Medicines

1

Committee Members

Dr Taher Abu-ElSamen, HHC, SG Dr Laila Jarrar, JFDA, Drug Director Dr Wafa Nsour, RMS , Pharmacy & Drug Director Dr Khawla Abu Hamour, JUH ,Pharmacy Director Dr Sana Naffa, WHO Dr Lama Al. Homoud, MOH, Clinical Pharmacy Director

2

Background

Clinical guidelines and treatment protocols are two of the major ways to ensure that the health care treatment options provided to populations are the best and most appropriate that the country could afford

3

Background

Standardization of protocols in a selected disease area by using the Rational Drug List

Increasing the acceptability/impact of RDL and reducing variation/inequity in current practices

4

1.Encouraging Best Practice / Improve Rational Use of Medicine

2.Evidence Based Decision Making for the (RDL)

3.Capacity Building in Civil Society

Priority Areas in Jordan’s MeTA Workplan

5

Scope of Work

Improve rational use of medicines: Consolidation and implementation of Standard

Treatment Guidelines Working with physicians and pharmacists to improve

prescribing behavior through training &continuing professional educational programs

Promoting the use of standard treatment guidelines

6

Improve rational use of medicines

Strategies adopted by MeTA / Jordan: Strategy I: Assessment and gap analysis Strategy II: Development and Implementation

plan for the Standard Treatment Guidelines Strategy III: Evaluation of a pilot area and

Multi-Sectoral Dissemination

7

Strategy I: Assessment and gap analysis

Activities: Assessing the current guidelines used in different

sectors Performing gap analysis of the current situation;

what standards are used, what services are covered, are these standards implemented?

8

Strategy I:Assessment and gap analysis

Activities: Reviewing the perception and use of the existing

treatment guidelines Knowledge, Attitude and Practice Study (KAP study)

Defining the committee targets and future steps in developing, adopting or consolidating the standards

Identifying the scope, purpose and use of these guidelines

9

Strategy II: Development and Implementation plan for the STG

Activities:• Finalizing and approving STG• Disseminating the guidelines in the pilot area through

orientation and training sessions • Involving the Hospital Pharmacy and Therapeutic

committees to activate their role in the implementation and monitoring processes

10

Strategy III:Evaluation of a pilot area & Multi-Sectoral dissemination

Activities:

Evaluate the compliance with STG in the pilot areaPrepare an advocacy tool using evidence and figures on cost containment and efficiencies in medicine expenditureUse Multi-Sectoral approach towards a national program to promote rational use of medicines

11

Work plan Sub-activities

1- Gap Analysis and situation analysis for the availability and use of STG in health facilities in Jordan:

a. Formulate a technical work group from public health institutions (MOH, JFDA, RMS and JUH)

b. Design a tool for collecting data regarding availability of the STG and the compliance to these standards

c. Conducting a comparative study with international STG

d.  Analysis of findings, conclusion and recommendations

Work plan Sub-activities

2- Three regional workshops to build consensus and get feedback from all parties on the final STG draft

3- Finalizing and approving STG

4- produce copies of the STG with job aids, posters and other materials to be used in public health facilities

13

Performance Progress and Evaluation

. Gap analysis and availability of existing guidelines Strategy developed and disseminated Finalization and approval of the STG Dissemination of guidelines in the pilot area Evaluate the compliance with standards in the pilot

area Continuing professional education programs

14

Means of VerificationPerformance Indicators

Gap analysis and assessment report finalized Workshop conducted Pilot conducted Report to be delivered CPE Programs done

15

Expected outcomes

The establishment of a multi-stakeholder approach that will be working towards increasing transparency focusing on the regulations, selection, procurement, and distribution of medicines

Strengthening governance Maximizing cost benefit utilization of medicines by

healthcare professionals

16

National Institute for Clinical Excellence (NICE)

An organization that is responsible for providing national guidance on promoting good health

A training workshop was conducted by NICE on Using Health Technology Assessment to inform decision-making in healthcare March 2009

Another workshop is planned for mid June 2009 to start with a pilot disease oriented STG (Hypertension)

17

National Institute for Clinical Excellence (NICE)

NICE involvement can be of benefit in two areas of strategic importance for improving the transparency of the way our healthcare system functions:

A) Best practice (STG), including harmonization of existing ones and methods and processes of adapting or developing new ones in high burden of disease areas

B) RDL including the methods and processes of making and listing and delisting decisions, considerations of cost effectiveness and of affordability

18

19